Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Achievement of HbA1c and body weight loss composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D: post-hoc analysis from SUSTAIN FORTE
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.